As urged by the AHA and others, a Centers for Medicare & Medicaid Services advisory panel today recommended that the agency not finalize for 2018 a proposal that would drastically cut Medicare payments for drugs acquired under the 340B Drug Pricing Program. In July, CMS proposed to pay separately-payable, non-pass-through drugs (other than vaccines) purchased through the 340B program at the average sales price minus 22.5%, rather than ASP plus 6%. Instead of implementing the proposal, CMS’s Advisory Panel on Hospital Outpatient Payment today recommended that the agency collect data from public comment and other sources about the proposal’s impact and how CMS should shift the savings if such a cut were implemented. In addition, the HOP Panel urged CMS to assess the proposal’s regulatory burden, especially from a proposed CMS modifier that differs from some state Medicaid program methodology. Testifying on behalf of the AHA at today’s hearing, Peegan Townsend, vice president of government affairs at MedStar Health, and Kathy Talbot, MedStar’s vice president for rates and reimbursement, discussed how CMS’s proposed payment cut would threaten access to care for patients in vulnerable communities. For example, MedStar Health uses 340B savings to help fund a no-charge clinic for uninsured patients in Baltimore; an after-hours clinic that provides free health care at a Washington, D.C. homeless shelter; and subsidies for discharge prescriptions and transportation for underserved populations in southern Maryland. The AHA has urged CMS to abandon the 340B proposal and instead take direct action to halt the unchecked, unsustainable increases in the cost of drugs. Comments on CMS’s proposal are due Sept. 11.

Related News Articles

Headline
The House Ways and Means Subcommittees on Health and Oversight held a joint hearing today to discuss lessons learned, challenges and opportunities to improve…
Headline
The AHA today expressed support for the Medicare Mental Health Inpatient Equity Act, a bill that would eliminate the 190-day lifetime limit on inpatient…
Headline
Rep. Doris Matsui, D-Calif., and Sen. Peter Welch, D-Vt., today introduced the 340B Patients Act, AHA-supported legislation that would codify 340B providers'…
Headline
The AHA July 16 filed an amicus brief in the U.S. District Court for the District of Colorado in defense of the state’s 340B contract pharmacy law prohibiting…
Headline
The U.S. District Court for the Eastern District of Missouri July 11 granted a motion by the state to dismiss claims by AbbVie that the state’s 340B contract…
Headline
The AHA July 8 wrote in opposition to the “Patient Access to Higher Quality Health Care Act” (H.R. 4002), which would repeal current law banning the creation…